Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT-11 in mild to moderate ulcerative colitis
ISRCTN14296856Phase 2Completed
- Sponsor
- Landos Biopharma, Inc.
- Start
- Mar 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of omilancor in autoimmune colitis (3 arms), sponsored by Landos Biopharma, Inc. Primary endpoint: Clinical remission rate at Week 12. Started Mar 2019; status: completed.
02
Drugs
omilancor
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ISRCTN14296856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14296856.